ArticleBreast (Edinburgh, Scotland)2020

Pathologic response at the epicenter of the treatment decision-making process in Human Epidermal Receptor-Type 2 overexpressing (Her2+) Early Breast Cancer (EBC): Challenges and opportunities for financially-constrained healthcare systems.

Max S ManoPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.